These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1503 related articles for article (PubMed ID: 32422178)
1. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. George PM; Wells AU; Jenkins RG Lancet Respir Med; 2020 Aug; 8(8):807-815. PubMed ID: 32422178 [TBL] [Abstract][Full Text] [Related]
2. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Ferrara F; Granata G; Pelliccia C; La Porta R; Vitiello A Eur J Clin Pharmacol; 2020 Nov; 76(11):1615-1618. PubMed ID: 32594204 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. Vitiello A; Pelliccia C; Ferrara F SN Compr Clin Med; 2020; 2(10):1709-1712. PubMed ID: 32875276 [TBL] [Abstract][Full Text] [Related]
4. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
5. Dapsone and doxycycline could be potential treatment modalities for COVID-19. Farouk A; Salman S Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778 [No Abstract] [Full Text] [Related]
6. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China. Zhang L; Dong L; Ming L; Wei M; Li J; Hu R; Yang J BMC Pregnancy Childbirth; 2020 Jul; 20(1):394. PubMed ID: 32641013 [TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular implications of SARS-CoV-2 infection: A literature review]. García-Saavedra MB; Rosales-Gutiérrez RR; Valverde E; Chumbes-Aguirre M; Alvarado R; Polo R; Azañero R; Chávez C Medwave; 2020 Aug; 20(7):e8008. PubMed ID: 32877391 [TBL] [Abstract][Full Text] [Related]
9. Potential effects of curcumin in the treatment of COVID-19 infection. Zahedipour F; Hosseini SA; Sathyapalan T; Majeed M; Jamialahmadi T; Al-Rasadi K; Banach M; Sahebkar A Phytother Res; 2020 Nov; 34(11):2911-2920. PubMed ID: 32430996 [TBL] [Abstract][Full Text] [Related]
10. Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea? Uyaroğlu OA; Güven GS; Güllü İ J Infect Dev Ctries; 2020 Aug; 14(8):844-846. PubMed ID: 32903227 [TBL] [Abstract][Full Text] [Related]
11. Teicoplanin: an alternative drug for the treatment of COVID-19? Baron SA; Devaux C; Colson P; Raoult D; Rolain JM Int J Antimicrob Agents; 2020 Apr; 55(4):105944. PubMed ID: 32179150 [TBL] [Abstract][Full Text] [Related]
13. [Characteristics of SARS-CoV-2 and potential pharmacological treatment]. Pawlik L; Śpiołek E; Fichna J; Tarasiuk A Postepy Biochem; 2020 May; 66(2):83-90. PubMed ID: 32700510 [TBL] [Abstract][Full Text] [Related]
14. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial. Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial. Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299 [TBL] [Abstract][Full Text] [Related]
16. A comparative overview of COVID-19, MERS and SARS: Review article. Liu J; Xie W; Wang Y; Xiong Y; Chen S; Han J; Wu Q Int J Surg; 2020 Sep; 81():1-8. PubMed ID: 32730205 [TBL] [Abstract][Full Text] [Related]
17. Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. Leyfman Y; Erick TK; Reddy SS; Galwankar S; Nanayakkara PWB; Di Somma S; Sharma P; Stawicki SP; Chaudry IH Shock; 2020 Oct; 54(4):438-450. PubMed ID: 32649367 [TBL] [Abstract][Full Text] [Related]
18. The novel zoonotic COVID-19 pandemic: An expected global health concern. Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085 [TBL] [Abstract][Full Text] [Related]
19. [Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures]. Wang J; Wang BJ; Yang JC; Wang MY; Chen C; Luo GX; He WF Zhonghua Shao Shang Za Zhi; 2020 Aug; 36(8):691-697. PubMed ID: 32174095 [TBL] [Abstract][Full Text] [Related]
20. Viral Coagulopathy in Patients With COVID-19: Treatment and Care. Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]